MX2023005179A - Proteínas de unión que reconocen antígeno ha-1 y usos de las mismas. - Google Patents

Proteínas de unión que reconocen antígeno ha-1 y usos de las mismas.

Info

Publication number
MX2023005179A
MX2023005179A MX2023005179A MX2023005179A MX2023005179A MX 2023005179 A MX2023005179 A MX 2023005179A MX 2023005179 A MX2023005179 A MX 2023005179A MX 2023005179 A MX2023005179 A MX 2023005179A MX 2023005179 A MX2023005179 A MX 2023005179A
Authority
MX
Mexico
Prior art keywords
antigen
binding proteins
proteins recognizing
recognizing
binding
Prior art date
Application number
MX2023005179A
Other languages
English (en)
Inventor
Ribhu Nayar
Gavin Macbeath
Sonal Jangalwe
Mollie M Jurewicz
Andrew S Basinski
Qikai Xu
Antoine J Boudot
Tomasz Kula
Original Assignee
Tscan Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tscan Therapeutics Inc filed Critical Tscan Therapeutics Inc
Publication of MX2023005179A publication Critical patent/MX2023005179A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464401—Neoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)

Abstract

En la presente se proporcionan proteínas de unión que reconocen el antígeno HA - 1 y usos de las mismas.
MX2023005179A 2020-11-06 2021-11-08 Proteínas de unión que reconocen antígeno ha-1 y usos de las mismas. MX2023005179A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063110851P 2020-11-06 2020-11-06
US202063111462P 2020-11-09 2020-11-09
US202063129804P 2020-12-23 2020-12-23
US202163175350P 2021-04-15 2021-04-15
PCT/US2021/058382 WO2022099100A2 (en) 2020-11-06 2021-11-08 Binding proteins recognizing ha-1 antigen and uses thereof

Publications (1)

Publication Number Publication Date
MX2023005179A true MX2023005179A (es) 2023-07-13

Family

ID=81458633

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023005179A MX2023005179A (es) 2020-11-06 2021-11-08 Proteínas de unión que reconocen antígeno ha-1 y usos de las mismas.

Country Status (10)

Country Link
US (1) US20230398217A1 (es)
EP (1) EP4240490A2 (es)
JP (1) JP2023549765A (es)
KR (1) KR20230117576A (es)
AU (2) AU2021323388C1 (es)
CA (1) CA3197255A1 (es)
IL (1) IL302616A (es)
MX (1) MX2023005179A (es)
TW (1) TW202227499A (es)
WO (1) WO2022099100A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024130009A1 (en) 2022-12-14 2024-06-20 Yale University Compositions and methods of use thereof for the treatment of virally driven cancers

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2598528A1 (en) * 2010-07-28 2013-06-05 Immunocore Ltd. T cell receptors
BR112019005633A8 (pt) * 2016-09-23 2023-04-11 Hutchinson Fred Cancer Res Tcrs específicos para antigênio ha-1 de histocompatibilidade (h) menor e usos dos mesmos

Also Published As

Publication number Publication date
WO2022099100A2 (en) 2022-05-12
AU2021323388C1 (en) 2022-10-27
AU2022241563A1 (en) 2022-11-03
CA3197255A1 (en) 2022-05-12
KR20230117576A (ko) 2023-08-08
TW202227499A (zh) 2022-07-16
US20230398217A1 (en) 2023-12-14
EP4240490A2 (en) 2023-09-13
WO2022099100A3 (en) 2022-06-16
AU2021323388B2 (en) 2022-07-28
JP2023549765A (ja) 2023-11-29
AU2021323388A1 (en) 2022-05-26
IL302616A (en) 2023-07-01

Similar Documents

Publication Publication Date Title
MX2022003718A (es) Anticuerpos que se unen a cd39 y sus usos.
MX2020003125A (es) Conjugado de anticuerpo-derivado de pirrolobenzodiazepina.
MY194032A (en) Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof
AU2021311470A1 (en) Binding proteins recognizing SARS-CoV-2 antigens and uses thereof
ZA202000027B (en) Constructs specifically recognizing glypican 3 and uses thereof
PH12019502087A1 (en) Anti-par2 antibodies and uses thereof
EP4025602A4 (en) TSLP-BINDING ANTIBODIES AND THEIR USES
WO2018187356A3 (en) Protein antigens and uses thereof
WO2019241430A3 (en) Antibody-oligonucleotide conjugates
AU2018338322A1 (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
MX2021008216A (es) Anticuerpos anti-tigit.
MX2021013417A (es) Polipeptidos de union a la proteina del miembro a de la familia 12 del dominio de lectina tipo c (clec12a) y sus usos.
ZA202106602B (en) Claudin 6 antibodies and uses thereof
EP4126938A4 (en) ANTIBODIES BINDING TO SIGLEC15 AND THEIR USES
AU2019321490A8 (en) Ox40-binding polypeptides and uses thereof
ZA202102546B (en) Methods for identifying free thiols in proteins
MX2021001129A (es) Metodo de purificacion de antigenos.
MX2023005179A (es) Proteínas de unión que reconocen antígeno ha-1 y usos de las mismas.
CL2020003391A1 (es) Proteína de unión al antígeno anti-steap1
MX2023012141A (es) Peptidos inmunogenicos magec2, proteinas de union que reconocen peptidos inmunogenicos magec2, y usos de estos.
MX2023012111A (es) Proteinas de union que reconocen el antigeno ha-2 y usos de estas.
EP3822284A4 (en) FOR SMO PROTEIN SPECIFIC EPITOPE, ANTIBODIES FOR ITS RECOGNITION AND COMPOSITION WITH IT
EP3976656A4 (en) ALK7 BINDING PROTEINS AND THEIR USES
WO2019036399A3 (en) METHOD OF CONTIGATION OF ANTIBODIES
WO2023086477A3 (en) Binding proteins recognizing hpv16 e7 antigen and uses thereof